BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 29204978)

  • 1. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
    Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
    Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
    Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
    Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
    Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
    World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma.
    Maurel M; Jalvy S; Ladeiro Y; Combe C; Vachet L; Sagliocco F; Bioulac-Sage P; Pitard V; Jacquemin-Sablon H; Zucman-Rossi J; Laloo B; Grosset CF
    Hepatology; 2013 Jan; 57(1):195-204. PubMed ID: 22865282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
    Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
    Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells.
    Kwack MH; Choi BY; Sung YK
    Mol Cells; 2006 Apr; 21(2):224-8. PubMed ID: 16682817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
    Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
    Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling.
    Magistri P; Leonard SY; Tang CM; Chan JC; Lee TE; Sicklick JK
    J Surg Res; 2014 Apr; 187(2):377-85. PubMed ID: 24439425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
    Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
    FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
    Gao W; Kim H; Ho M
    PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.
    Sun CK; Chua MS; He J; So SK
    Neoplasia; 2011 Aug; 13(8):735-47. PubMed ID: 21847365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
    Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
    Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.
    Liu X; Wang SK; Zhang K; Zhang H; Pan Q; Liu Z; Pan H; Xue L; Yen Y; Chu PG
    Carcinogenesis; 2015 Feb; 36(2):232-42. PubMed ID: 25542894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
    Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
    Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Glycanation and Convertase Maturation of Soluble Glypican-3 in Inhibiting Proliferation of Hepatocellular Carcinoma Cells.
    Saad A; Liet B; Joucla G; Santarelli X; Charpentier J; Claverol S; Grosset CF; Trézéguet V
    Biochemistry; 2018 Feb; 57(7):1201-1211. PubMed ID: 29345911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation of primary human hepatocytes in hepatocellular carcinoma.
    Montalbano M; Rastellini C; Wang X; Corsello T; Eltorky MA; Vento R; Cicalese L
    Int J Oncol; 2016 Mar; 48(3):1205-17. PubMed ID: 26717856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
    Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
    Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
    Filmus J; Capurro M
    FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Glypican-3 Cleavage Results in Reduced Cell Proliferation in a Liver Cancer Cell Line.
    Schepers EJ; Lake C; Glaser K; Bondoc AJ
    J Surg Res; 2023 Feb; 282():118-128. PubMed ID: 36272230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
    DU JL; Wei LX; Wang YL
    Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.